Skip to Content

Upper Limb Spasticity

Upper limb spasticity is a neurological condition that affects movement in the arms and/or hands and occurs most commonly after a stroke or traumatic brain injury. The condition is associated with muscle stiffness, spasms, and inability to perform daily tasks.1

In February 2021, Revance announced positive topline Phase 2 data supporting advancement of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity.
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Not an actual patient


Estimated number of people worldwide who suffer from spasticity.2


Estimated portion of patient population currently receiving treatment.3


Estimated number of people in the U.S. who suffer from upper limb spasticity.2

Botulinum toxin treatment is the standard of care for management of focal upper limb spasticity. Other treatment options include muscle relaxants, physical therapy, splints, casts and braces, electrical stimulation, and surgery. Long-acting symptom relief is needed to address current challenges and is an unmet need of upper limb spasticity treatment.

3 months

Improvement of spasticity symptoms with currently approved botulinum toxin treatment may last an average of three months5


Survey of patients with spasticity overwhelmingly (72%) indicated the desire for a longer lasting treatment6


1. Spasticity. American Association of Neurological Surgeons. Retrieved from: Accessed 9/29/2020

2. What is spasticity? Life with Spasticity. Retrieved from: Accessed 10/09/2020

3. Munin M et al. Methodology of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, 36-Week, Multicenter Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury (JUNIPER). Poster presented at 2019 TOXINS. 16-19 January, 2019. Copenhagen, Denmark.

4. Spasticity. American Association of neurological Surgeons. Retrieved from: Assessed: 11/16/2020

5. Simpson DM, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016, May 10;86(19): 1818–1826.

6. Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in spasticity. Frontiers in Neurology, 2020, Volume 11, Article 388.

Back to top